Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.

The U.S. Food and Drug Administration made the decision to grant Breakthrough Therapy Designation to Mirati Therapeutics’ adagrasib for the potential treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.